Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

9.16
+0.25002.81%
Post-market: 9.200.0400+0.44%19:59 EST
Volume:4.10M
Turnover:37.33M
Market Cap:1.95B
PE:-6.37
High:9.29
Open:9.08
Low:8.95
Close:8.91
52wk High:16.44
52wk Low:5.79
Shares:213.05M
Float Shares:183.00M
Volume Ratio:0.59
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4387
EPS(LYR):-1.2227
ROE:-54.85%
ROA:-26.66%
PB:2.98
PE(LYR):-7.49

Loading ...

Ocular Therapeutix gewährt neuen Mitarbeitern Aktienanreize gemäß Nasdaq-Regel

Reuters
·
Yesterday

Ocular Therapeutix Grants Inducement Equity Awards to New Employees

Reuters
·
Yesterday

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Yesterday

Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks

TIPRANKS
·
Feb 06

Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says

MT Newswires Live
·
Feb 06

Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Feb 05

Ocular Therapeutix Q4 EPS $(0.29) Beats $(0.32) Estimate, Sales $13.250M Miss $16.128M Estimate

Benzinga
·
Feb 05

Ocular Therapeutix Q4 revenue falls 22.4% yr/yr

Reuters
·
Feb 05

Earnings Flash (OCUL) Ocular Therapeutix Posts Q4 Loss $0.29 a Share, vs. FactSet Est of $0.32 Loss

MT Newswires Live
·
Feb 05

Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting

Reuters
·
Feb 05

Ocular Therapeutix Inc. meldet für das Gesamtjahr 2025 einen Anstieg des Eigenkapitals auf 654,31 Mio. USD um 107 Prozent

Reuters
·
Feb 05

BRIEF-Ocular Therapeutix Q4 EPS USD -0.29

Reuters
·
Feb 05

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

THOMSON REUTERS
·
Feb 05

Ocular Therapeutix Q4 Product Revenue USD 13.25 Million

THOMSON REUTERS
·
Feb 05

Ocular Therapeutix Q4 Net Income USD -64.654 Million

THOMSON REUTERS
·
Feb 05

A Look At Ocular Therapeutix (OCUL) Valuation After Mixed Earnings And New Executive Appointments

Simply Wall St.
·
Jan 29

Ocular Therapeutix Grants Inducement Equity Awards to New Chief Commercial Officer

Reuters
·
Jan 26

Ocular Therapeutix Names Jason Robins Interim Chief Financial Officer

Reuters
·
Jan 26

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 24